Financial Data and Key Metrics Changes - In Q4 2025, net sales were approximately $693 million, a 3.9% increase from $668 million in Q4 2024. On a currency neutral basis, this represents a 1.7% year-over-year increase [11] - Full year 2025 net sales were $2.583 billion, a 0.7% increase from $2.567 billion in 2024. On a currency neutral basis, sales were essentially flat compared to 2024 [17][18] - Q4 GAAP gross margin was 49.8%, down from 51.2% in Q4 2024. Non-GAAP gross margin was 52.5%, compared to 53.9% in the previous year [13][14] - Full year non-GAAP gross margin was 53.3%, down from 55% in 2024, primarily due to reduced fixed manufacturing absorption and higher material costs [19] Business Segment Data and Key Metrics Changes - Clinical diagnostics segment sales in Q4 2025 were approximately $425 million, an 8.4% increase from $393 million in Q4 2024, driven by higher sales of quality control and blood typing products [13] - Life science segment sales in Q4 2025 were $268 million, a 2.6% decrease from $275 million in Q4 2024, impacted by constrained academic research and biotech funding [11][12] - The ddPCR portfolio posted mid-single-digit year-over-year growth in Q4, driven by the success of the QX700 platform [12][26] Market Data and Key Metrics Changes - Currency neutral sales decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific [12][18] - In biopharma, funding conditions improved in the second half of 2025, with expectations for a modest recovery in 2026 [9] - Cautious spending persisted in academia and government, affecting instrument demand [8] Company Strategy and Development Direction - The company plans to advance several product launches in 2026, including an IVD version of the QX600 and additional high-value ddPCR assays [10] - Focus on disciplined innovation is central to the long-term growth strategy, with an emphasis on operational performance and cost structure management [10][31] - The company is actively looking for additional assets to accelerate top-line growth and margin expansion [30] Management's Comments on Operating Environment and Future Outlook - Management sees early signs of stabilization across core markets, with improvements in NIH funding and biopharma funding [28] - The company remains focused on driving long-term value and is witnessing the impact of a performance-related approach [29] - Management is optimistic about the growth potential of the ddPCR business and the overall diagnostics segment [28][29] Other Important Information - Free cash flow for 2025 was approximately $375 million, representing a conversion ratio of 138% for free cash flow to non-GAAP net income [23] - The company retired 1.2 million shares through its buyback program at a total cost of approximately $296 million during 2025 [23][24] - Non-GAAP guidance for 2026 anticipates currency neutral revenue growth between 0.5% and 1.5% [24] Q&A Session Summary Question: About the ddPCR business growth - Management noted strong quarterly growth in the ddPCR business, driven by the QX700 platform and ongoing reagent sales from a large installed base [34][35] Question: Process Chromatography changes - Management explained that recent changes in vaccine production strategies impacted the Process Chromatography forecast, leading to a conservative outlook [37][38] Question: Operating margins outlook - Management provided insights on the operating margin forecast, highlighting the impact of Process Chromatography and Q4 costs that are not expected to recur [39][40] Question: Clinical diagnostics growth - Management discussed the muted growth in clinical diagnostics, attributing it to a mix of product performance and geographic factors [57][59] Question: Buyback strategy - Management clarified that the lack of buybacks in Q4 does not signal any specific strategy, as they are actively looking for acquisition opportunities [63][64]